The prolyl oligopeptidase inhibitor KYP‑2047 is not readily bioavailable to bloodstream form trypanosomes and human myelocytic leukemia cells. (2015). Journal of Pharmaceutical Negative Results, 6(1), 7-10. https://mail.pnrjournal.com/index.php/home/article/view/84